SANOFI-ADR (SNY) Stock Fundamental Analysis
NASDAQ:SNY - US80105N1054 - ADR
50.11 USD
-0.19 (-0.38%)
50.11 USD
0 (0%)
Taking everything into account, SNY scores 6 out of 10 in our fundamental rating. SNY was compared to 193 industry peers in the Pharmaceuticals industry. While SNY has a great profitability rating, there are some minor concerns on its financial health. SNY scores decently on growth, while it is valued quite cheap. This could make an interesting combination. SNY also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
In the past year SNY was profitable.
In the past year SNY had a positive cash flow from operations.
In the past 5 years SNY has always been profitable.
SNY had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of SNY (11.05%) is better than 92.23% of its industry peers.
SNY's Return On Equity of 19.73% is amongst the best of the industry. SNY outperforms 91.71% of its industry peers.
Looking at the Return On Invested Capital, with a value of 13.84%, SNY belongs to the top of the industry, outperforming 92.23% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for SNY is significantly below the industry average of 15.38%.
The 3 year average ROIC (7.31%) for SNY is below the current ROIC(13.84%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 19.73% | ||
| ROIC | 13.84% |
ROA(3y)5.02%
ROA(5y)6.2%
ROE(3y)8.55%
ROE(5y)10.84%
ROIC(3y)7.31%
ROIC(5y)7.07%
1.3 Margins
The Profit Margin of SNY (20.35%) is better than 93.26% of its industry peers.
SNY's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 23.59%, SNY belongs to the top of the industry, outperforming 90.16% of the companies in the same industry.
In the last couple of years the Operating Margin of SNY has grown nicely.
SNY has a Gross Margin of 71.70%. This is in the better half of the industry: SNY outperforms 79.79% of its industry peers.
SNY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.59% | ||
| PM (TTM) | 20.35% | ||
| GM | 71.7% |
OM growth 3Y-2.73%
OM growth 5Y1.75%
PM growth 3Y-7.54%
PM growth 5Y11.4%
GM growth 3Y0.71%
GM growth 5Y0.58%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so SNY is creating value.
SNY has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for SNY remains at a similar level compared to 5 years ago.
SNY has a better debt/assets ratio than last year.
2.2 Solvency
The Debt to FCF ratio of SNY is 2.21, which is a good value as it means it would take SNY, 2.21 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 2.21, SNY belongs to the best of the industry, outperforming 92.23% of the companies in the same industry.
SNY has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
SNY has a Debt to Equity ratio of 0.21. This is comparable to the rest of the industry: SNY outperforms 45.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 2.21 | ||
| Altman-Z | N/A |
ROIC/WACC1.92
WACC7.21%
2.3 Liquidity
A Current Ratio of 1.27 indicates that SNY should not have too much problems paying its short term obligations.
The Current ratio of SNY (1.27) is worse than 74.61% of its industry peers.
A Quick Ratio of 0.94 indicates that SNY may have some problems paying its short term obligations.
SNY's Quick ratio of 0.94 is on the low side compared to the rest of the industry. SNY is outperformed by 75.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 0.94 |
3. Growth
3.1 Past
SNY shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.20%.
SNY shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 5.10% yearly.
Looking at the last year, SNY shows a small growth in Revenue. The Revenue has grown by 6.45% in the last year.
SNY shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.31% yearly.
EPS 1Y (TTM)-2.2%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%-8.09%
Revenue 1Y (TTM)6.45%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-6.99%
3.2 Future
SNY is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.38% yearly.
The Revenue is expected to grow by 4.01% on average over the next years.
EPS Next Y3.91%
EPS Next 2Y6.53%
EPS Next 3Y6.33%
EPS Next 5Y6.38%
Revenue Next Year0.18%
Revenue Next 2Y3.45%
Revenue Next 3Y4.32%
Revenue Next 5Y4.01%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 11.34, the valuation of SNY can be described as very reasonable.
Based on the Price/Earnings ratio, SNY is valued cheaply inside the industry as 89.64% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of SNY to the average of the S&P500 Index (27.14), we can say SNY is valued rather cheaply.
With a Price/Forward Earnings ratio of 9.81, the valuation of SNY can be described as very reasonable.
85.49% of the companies in the same industry are more expensive than SNY, based on the Price/Forward Earnings ratio.
SNY is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.80, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.34 | ||
| Fwd PE | 9.81 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of SNY indicates a rather cheap valuation: SNY is cheaper than 97.41% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of SNY indicates a rather cheap valuation: SNY is cheaper than 90.67% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.41 | ||
| EV/EBITDA | 5.72 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
SNY has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)2.9
PEG (5Y)2.22
EPS Next 2Y6.53%
EPS Next 3Y6.33%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 4.48%, SNY is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 3.83, SNY pays a better dividend. On top of this SNY pays more dividend than 96.37% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.34, SNY pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.48% |
5.2 History
The dividend of SNY has a limited annual growth rate of 4.30%.
SNY has been paying a dividend for at least 10 years, so it has a reliable track record.
The dividend of SNY decreased in the last 3 years.
Dividend Growth(5Y)4.3%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
34.82% of the earnings are spent on dividend by SNY. This is a low number and sustainable payout ratio.
SNY's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP34.82%
EPS Next 2Y6.53%
EPS Next 3Y6.33%
50.11
-0.19 (-0.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners40.34%
Inst Owner Change-5.26%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap122.22B
Analysts80
Price Target63.72 (27.16%)
Short Float %0.15%
Short Ratio1.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.48% |
Yearly Dividend2.21
Dividend Growth(5Y)4.3%
DP34.82%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.86%
Min EPS beat(2)-2.29%
Max EPS beat(2)6.02%
EPS beat(4)2
Avg EPS beat(4)4.01%
Min EPS beat(4)-2.29%
Max EPS beat(4)14.5%
EPS beat(8)4
Avg EPS beat(8)2.17%
EPS beat(12)7
Avg EPS beat(12)2.71%
EPS beat(16)11
Avg EPS beat(16)3.44%
Revenue beat(2)0
Avg Revenue beat(2)-0.96%
Min Revenue beat(2)-1.3%
Max Revenue beat(2)-0.63%
Revenue beat(4)1
Avg Revenue beat(4)-0.71%
Min Revenue beat(4)-4.57%
Max Revenue beat(4)3.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.12%
Revenue beat(12)4
Avg Revenue beat(12)9.26%
Revenue beat(16)8
Avg Revenue beat(16)21.08%
PT rev (1m)-2.04%
PT rev (3m)-5.69%
EPS NQ rev (1m)-5.14%
EPS NQ rev (3m)-11.62%
EPS NY rev (1m)-4.91%
EPS NY rev (3m)-4.93%
Revenue NQ rev (1m)-1.22%
Revenue NQ rev (3m)-6.9%
Revenue NY rev (1m)-1.33%
Revenue NY rev (3m)-1.33%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.34 | ||
| Fwd PE | 9.81 | ||
| P/S | 1.54 | ||
| P/FCF | 10.41 | ||
| P/OCF | 9.21 | ||
| P/B | 1.5 | ||
| P/tB | 11.28 | ||
| EV/EBITDA | 5.72 |
EPS(TTM)4.42
EY8.82%
EPS(NY)5.11
Fwd EY10.19%
FCF(TTM)4.81
FCFY9.6%
OCF(TTM)5.44
OCFY10.85%
SpS32.45
BVpS33.46
TBVpS4.44
PEG (NY)2.9
PEG (5Y)2.22
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 19.73% | ||
| ROCE | 16.7% | ||
| ROIC | 13.84% | ||
| ROICexc | 16.48% | ||
| ROICexgc | 66.95% | ||
| OM | 23.59% | ||
| PM (TTM) | 20.35% | ||
| GM | 71.7% | ||
| FCFM | 14.83% |
ROA(3y)5.02%
ROA(5y)6.2%
ROE(3y)8.55%
ROE(5y)10.84%
ROIC(3y)7.31%
ROIC(5y)7.07%
ROICexc(3y)8.13%
ROICexc(5y)7.97%
ROICexgc(3y)35.39%
ROICexgc(5y)35.54%
ROCE(3y)8.84%
ROCE(5y)8.55%
ROICexcg growth 3Y-13.63%
ROICexcg growth 5Y-1.43%
ROICexc growth 3Y-1.55%
ROICexc growth 5Y2.05%
OM growth 3Y-2.73%
OM growth 5Y1.75%
PM growth 3Y-7.54%
PM growth 5Y11.4%
GM growth 3Y0.71%
GM growth 5Y0.58%
F-Score7
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 2.21 | ||
| Debt/EBITDA | 0.75 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 58.05% | ||
| Profit Quality | 72.91% | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 0.94 | ||
| Altman-Z | N/A |
F-Score7
WACC7.21%
ROIC/WACC1.92
Cap/Depr(3y)73.02%
Cap/Depr(5y)67.36%
Cap/Sales(3y)6.35%
Cap/Sales(5y)5.97%
Profit Quality(3y)113.82%
Profit Quality(5y)104.22%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.2%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%-8.09%
EPS Next Y3.91%
EPS Next 2Y6.53%
EPS Next 3Y6.33%
EPS Next 5Y6.38%
Revenue 1Y (TTM)6.45%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-6.99%
Revenue Next Year0.18%
Revenue Next 2Y3.45%
Revenue Next 3Y4.32%
Revenue Next 5Y4.01%
EBIT growth 1Y15.64%
EBIT growth 3Y1.33%
EBIT growth 5Y5.12%
EBIT Next Year34.08%
EBIT Next 3Y14.6%
EBIT Next 5Y9.86%
FCF growth 1Y24.23%
FCF growth 3Y-11.46%
FCF growth 5Y-0.14%
OCF growth 1Y10.87%
OCF growth 3Y-4.79%
OCF growth 5Y3.31%